Cargando…

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

The development of drug-induced lupus remains a matter of concern in patients treated with anti-tumour necrosis factor (TNF) alpha. The incidence of such adverse effects is unknown. We undertook a retrospective national study to analyse such patients. Between June and October 2003, 866 rheumatology...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Bandt, Michel, Sibilia, Jean, Le Loët, Xavier, Prouzeau, Sebastian, Fautrel, Bruno, Marcelli, Christian, Boucquillard, Eric, Siame, Jean Louis, Mariette, Xavier
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1174953/ https://www.ncbi.nlm.nih.gov/pubmed/15899041 http://dx.doi.org/10.1186/ar1715

Ejemplares similares

Anti-TNF-alpha-induced lupus
por: De Bandt, Michel
Publicado: (2019)

The role of tumor necrosis factor-alpha in systemic lupus erythematosus
por: Aringer, Martin, et al.
Publicado: (2008)

Depressive symptoms are associated with tumor necrosis factor alpha in systemic lupus erythematosus
por: Postal, Mariana, et al.
Publicado: (2016)

Mechanisms of Tumor Necrosis Factor-Alpha Inhibitor-Induced Systemic Lupus Erythematosus
por: Yen, Chung-Yang, et al.
Publicado: (2022)

Familial Aggregation of High Tumor Necrosis Factor Alpha Levels in Systemic Lupus Erythematosus
por: Mangale, Dorothy, et al.
Publicado: (2013)

Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients
por: de Bandt, Michel, et al.
Publicado: (2009)

Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey
por: Petitdemange, Arthur, et al.
Publicado: (2021)

Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis
por: Juge, Pierre-Antoine, et al.
Publicado: (2017)

Interferon Alpha in Systemic Lupus Erythematosus
por: Niewold, Timothy B., et al.
Publicado: (2010)

Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus
por: Sacre, Karim, et al.
Publicado: (2012)

Experience and impact of the COVID-19 pandemic in patients with systemic lupus erythematosus in France
por: Scherlinger, M., et al.
Publicado: (2022)

A case of lupus erythematosus profundus with severe ulceration that responded to tumor necrosis factor-alpha--blocking agents
por: Nakagomi, Daiki
Publicado: (2021)

Systemic lupus erythematosus and neutropaenia: a hallmark of haematological manifestations
por: Meyer, Aurore, et al.
Publicado: (2020)

Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists
por: Hamdi, Haïfa, et al.
Publicado: (2006)

Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis
por: Becker-Merok, Andrea, et al.
Publicado: (2006)

Cricoarytenoiditis as an Initial Manifestation of Systemic Lupus Erythematosus
por: Hougardy, Jean-Michel, et al.
Publicado: (2011)

Nucleosome is a necrosis inducer for lymphocytes: consequences in systemic lupus erythematosus
por: Decker, P, et al.
Publicado: (2001)

Anti-Tumor Necrosis Factor-α Induced Systemic Lupus Erythematosus()
por: Almoallim, Hani, et al.
Publicado: (2012)

Symptomatic multifocal avascular necrosis in an adolescent with neuropsychiatric systemic lupus erythematosus
por: Ekinci, Rabia Miray Kisla, et al.
Publicado: (2019)

Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database
por: Seror, Raphaele, et al.
Publicado: (2022)

Epidemiology and Characteristics of Spondyloarthritis in the Predominantly Afro-Descendant Population of Martinique, a French Caribbean Island
por: Louis-Sidney, Fabienne, et al.
Publicado: (2022)

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study
por: Tebib, Jacques, et al.
Publicado: (2009)

Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort
por: Fautrel, Bruno, et al.
Publicado: (2012)

Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data
por: Granger, Benjamin, et al.
Publicado: (2016)

Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity
por: Sellam, Jérémie, et al.
Publicado: (2009)

Phenotypic switch from non-active primary Sjögren's syndrome to severe systemic Lupus erythematosus after COVID-19 infection in an elderly man
por: Roger, Guillaume, et al.
Publicado: (2021)

Difficulties and Psychological Impact of the SARS-CoV-2 Pandemic in Patients with Systemic Lupus Erythematosus: A Nationwide Patient Association Study
por: Scherlinger, Marc, et al.
Publicado: (2022)

A case of systemic lupus erythematosus presenting as bilateral avascular necrosis of femur
por: Adikari, Madura, et al.
Publicado: (2016)

Interferon alpha associated with systemic lupus erythematosus is not intrinsically acid labile
Publicado: (1989)

Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: the French GR2 study
por: Larosa, Maddalena, et al.
Publicado: (2022)

Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency.
por: Tsutsumi, Y., et al.
Publicado: (1996)

Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic)
por: Hamidou, Mohamed, et al.
Publicado: (2021)

Avascular necrosis in pediatric systemic lupus erythematosus: a brief report and review of the literature
por: Gurion, Reut, et al.
Publicado: (2015)

Serum alpha–actinin antibody status in systemic lupus erythematosus and its potential in the diagnosis of lupus nephritis
por: Babaei, Mansour, et al.
Publicado: (2016)

Lupus Erythematosus
por: Gardiner, Frederick
Publicado: (1923)

Lupus Erythematosus
por: Ravogli, A.
Publicado: (1887)

Metabolic effects of tumour necrosis factor alpha in NMRI mice.
por: Mahony, S. M., et al.
Publicado: (1990)

Linear cutaneous lupus erythematosus/discoid lupus erythematosus in an adult
por: Mao, Qiu-Xia, et al.
Publicado: (2017)

Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study
por: Schlencker, Aurelien, et al.
Publicado: (2022)

Hepatic Necrosis: A Main Presentation of Systemic Lupus Erythematosus in a Previously Healthy Woman
por: Avijgan, Majid, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_oa5cc73asdhk2jkvo6tchcaih2